Mu-Yong Kim, Ph.D. Research Specialist College of Pharmacy Pharmacology and Toxicology mykim@pharmacy.arizona.edu Arizona Cancer Center Room 4949 1515 North Campbell Avenue Tucson, Arizona 85724 Telephone: (520) 626-9494 Fax: (520) 626-5623

Current Project : - Biological studies with G-quadruplex interactive agents and topoisomerase II inhibitors. Previous Projects : - Preclinical and clinical development of antibacterial agents. - Mechanism studies with ginsenoside. Family : Mi-Sook Sung (wife) and Yoon-Seo Kim (daughter) Publications 1. Kim MY, Lee KY, and Lee SK, Inductive effect of ginsenoside-Rg1 on Tyrosine Amino Transferase gene expression in rat primary hepatocyte cultures, Biochemistry and Molecular Biology International 34, 845-851 (1994) 2. Kwak JH and Kim MY, Construction of T-vector for direct cloning and expression of cloned genes in E. coli, Analytical Biochemistry 228, 178-180 (1995) 3. Kim MY, Oh JI, Song HK, Paek KS, and Kwak JH, Prevalence of strains resistant to the third generation cephalosporins among clinical isolates and identification of TEM type ?- lactamase from resistant strains by PCR method Yakhak Hoeji 39, 276-282 (1995) 4. Kim MY, Oh JI, Paek KS, Kim YZ, Kim IC, and Kwak JH, In vitro and in vivo activities of LB10522, a new catecholic cephalosporin, Antimicrobial Agents and Chemotherapy 40, 1825-1831 (1996) 5. Oh JI, Paek KS, Ahn MJ, Kim MY, Hong CY, Kim IC, and Kwak JH, In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone, Antimicrobial Agents and Chemotherapy 40, 1564-1568 (1996) 6. Song HK, Oh JI, Kim MY, Kim YZ, Kim IC, and Kwak JH, In vitro and in vivo activities of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum, Journal of Antimicrobial Chemotherapy 37, 711-726 (1996) 7. Kim MY, Paek KS, Kim IC, and Kwak JH, Bacterial resistance to LB20304, a new fluoroquinolone antibiotic, Archives of Pharmacal Research 19, 400-405 (1996) 8. Kim MY, Oh JI, Paek KS, Hong CY, Kim IC, and Kwak JH, In vitro activities of LB20304, a new fluoroquinolone, Archives of Pharmacal Research 19, 52-59 (1996) 9. Song HK, Nishino T, Seo MK, Kim MY, Lee YH, Kim IC, and Kwak JH, In vitro and in vivo evaluations of LB10517, a novel parenteral broad-spectrum cephalosporin, Archives of Pharmacal Research 19, 45-51 (1996) 10. Paek KS, Ahn MJ, Kim MY, Kim IC, and Kwak JH, Factors affecting in vitro activity of LB20304, a new fluoroquinolone, Archives of Pharmacal Research 19, 143-147 (1996) 11. Paek KS, Kim MY, Kim IC, and Kwak JH, Bactericidal activities of LB20304, a new fluoroquinolone, Archives of Pharmacal Research 19, 317-320 (1996) 12. Kwak JH, Kim MY, Paek KS, Kwon OH, Lee KW, and Kim IC, Antimicrobial activities of LB20304a, a new quinolone antibiotic, The Journal of Applied Pharmacology 4, 378-384 (1996) 13. Kim MY, Oh JI, Paek KS, Kim IC, Kwak JH, Action mechanism of LB10522, a new catechol-substituted cephalosporin, Yakhak Hoeji 40, 102-111 (1996) 14. M. J. Ahn, M. Y. Kim, K. S. Paek, I. C. Kim, J. H. Kwak, In vivo efficacy of LB20304a against experimental respiratory tract infection in mice, Yakhak Hoeji 40, 438-441 (1996) 15. M. J. Ahn, K. S. Paek, M. Y. Kim, I. C. Kim, J. H. Kwak, Post-antibiotic effect of LB20304, a new quinolone antibiotic, Yakhak Hoeji 40, 347-350 (1996) 16. Ahn MJ, Paek KS, Kim MY, Kim IC, and Kwak JH, Effects of a new fluoroquinolone LB20304a on microflora of caecum in mice, Yakhak Hoeji 40, 343-346 (1996) 17. Paek KS, Oh JI, Kim MY, Kim IC, and Kwak JH, In vitro and in vivo antibacterial activities of a new parenteral cephalosporin, LB10522, Yakhak Hoeji 40, 95-101 (1996) 18. Kwak JH, Kim JH, Kim MY, and Choi EC, Purification and characterization of Cop, a protein involved in the copy number control of plasmid pE194, Archives of Pharmacal Research 21, 291-297 (1998) 19. Lee CS, Ryu EJ, Oh SH, Paek KS, Kim MY, and Youn HS, Synthesis and antibacterial activities of novel C (3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens, Bioorganic and medicinal chemistry letters 10, 2123-2127 (2000) 20. Lee CS, Oh SH, Ryu EJ, Kim MY, and Paek KS, Synthesis and antibacterial activities of novel C (3)-aminopyrimidinyl substituted cephalosporins, Journal of Antibiotics 53, 1305- 1309 (2000) 21. Paek KS, Kim MY, Lee CS, and Youn H, In vitro and in vivo activity of LB10827, a new oral cephalosporin, against respiratory pathogens, Antimicrobial Agents and Chemotherapy, 44, 3272-3277 (2000) 22. Kwak JH, Kim MY, and Choi EC, A novel plasmid-mediated beta-lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Klebsiella pneumoniae, Archives of Pharmacal Research, 24(6), 590-596 (2001) 23. Duan W, Vankayalapati H, Rangan A, Kim MY, Sun D, Han H, Izbicka E, Nishioka D, Rha SY, Van Hoff D, and Hurley LH, Design and synthesis of Fluoroquinophenoxazines That Interact with G-Quadruplexes and Their Biological Effects, Molecular Cancer Therapeutics, 1, 103-120 (2001) 24. Kim MY, Vankayalapati H, Shin-ya K, Wierzba K, and Hurley LH, Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the intramolecular G-quadruplex, Journal of the American Chemical Society, 124 (10) 2098-2099 (2002) 25. Kim MY, Duan W, Guzman M, and Hurley LH, Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with a dual mechanism of action against topoisomerase II and G-quadruplex. Journal of Medicinal Chemistry, submit (2002) Poster Presentations 1. Kwak JH, Kim SI, Oh JI, Song HK, Kim MY, Seo MK, Jeong YN, Lee YH, Kim YZ, and Kim IC, In vitro and in vivo activities of LK10517, a novel catechol-substituted cephalosporin, Abs. No. F610, In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Orlando, FL (1994) 2. Kim MY, Song HK, Oh JI, Seo MK, Lee YH, Kim IC, and Kwak JH, LB10522, a new catechol-substituted cephalosporin : ?-Lactamase stabilities and biological activities, Abs. No. F42, In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA (1995) 3. Oh JI, Paek KS, Song HK, Kim MY, Kim YZ, Kim IC and Kwak JH, LB10522, a new catechol-substituted cephalosporin : In vitro and in vivo antibacterial activities, Abs. No. F41, In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA (1995) 4. Oh JI, Ahn MJ, Paek KS, Kim MY, Seo MK, Lee YH, Hong CY, Nam DH, Kim YZ. Kim IC, and Kwak JH, In vitro and in vivo antibacterial activities of LB20304, a new fluoronaphthyridone, Abs. No. F205, In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA (1995) 5. Nam DH, Kwak JH, Lee YH, Lee SK, Kim AR, Kim MY, Lee CH, Kim HJ, Choo YS and Kim IC, LB20304, a new generation of fluoroquinolone antibacterial agent Annual Meeting of the Korean Society of Applied Pharmacology, 6-11 (1997) 6. Kim MY, Paek KS, and Choo YS, SB-265805 (LB20304a): Selectivity between bacterial DNA gyrase and human topoisomerase II, Abs. No. F089, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 7. Kim MY, Paek KS, and Choo YS, SB-265805 (LB20304a): Post-antibiotic effects on Staphylococcus aureus and Escherichia coli, Abs. No. F088, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 8. Kim MY, Paek KS, and Choo YS, SB-265805 (LB20304a): In vitro antibacterial activity against respiratory tract pathogens, Abs. No. F093, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 9. Paek KS, Kim MY, and Choo YS, SB-265805 (LB20304a): In vitro antibacterial activity and spectrum, Abs. No. F092, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 10. Paek KS, Kim MY, and Choo YS, Prevalence of resistance to erythromycin and in vitro activity of SB-265805 (LB20304a) against gram-positive clinical isolates collected in Korea, Abs. No. F090, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 11. Paek KS, Kim MY, and Choo YS, SB-265805 (LB20304a): Bactericidal activity against S. aureus, E. coli and P. aeruginosa, Abs. No. F091, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 12. Paek KS, Kim MY, and Choo YS, SB-265805 (LB20304a): Bactericidal activity of against respiratory tract pathogens, Abs. No. F094, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 13. Hong CY, Kim YK, Nam DH, Choi H, Jang JH, Paek KS, and Kim MY, SB-265805 (LB20304a): SAR of the oxime-derivatized pyrrolidine. The importance of the oximiminoakyl group on in vitro antibacterial activity and pharmacokinetics, Abs. No. F095, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 14. Hong CY, Kim YK, Paek KS, and Kim MY, SB-265805 (LB20304a): The dramatic synergic effect of the methyloxime and aminomethyl groups of the C-7 pyrrolidine in In vitro antibacterial activity, Abs. No. F096, In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA (1998) 15. Kim MY, Paek KS, and Choo YS, SB-265805: In vitro antibacterial activity against respiratory tract pathogens, 41, In Program and abstracts of the 6th International Symposium on New Quinolones, Denver, Colorado (1998) 16. Kim MY, Paek KS, and Choo YS, SB-265805: Bactericidal activity of against respiratory tract pathogens, 42, In Program and abstracts of the 6th International Symposium on New Quinolones, Denver, Colorado (1998) 17. Kim MY, Paek KS, and Choo YS, Prevalence of resistance to erythromycin and in vitro activity of SB-265805 against gram-positive clinical isolates collected in Korea, 169, In Program and abstracts of the 6th International Symposium on New Quinolones, Denver, Colorado, (1998) 18. Paek KS, Kim MY, and Choo YS, SB-265805: In vitro antibacterial activity and spectrum, 170, In Program and abstracts of the 6th International Symposium on New Quinolones, Denver, Colorado (1998) 19. Kim MY, Paek KS, and Choo YS, SB-265805: Selectivity between bacterial DNA gyrase and human topoisomerase II, 189, In Program and abstracts of the 6th International Symposium on New Quinolones, Denver, Colorado (1998) 20. Kim MY, Paek KS, and Choo YS, SB-265805: Post-antibiotic effects on Staphylococcus aureus and Escherichia coli, 204, In Program and abstracts of the 6th International Symposium on New Quinolones, Denver, Colorado (1998) 21. Paek KS, Kim MY, and Choo YS, SB-265805: Bactericidal activity against S. aureus, E. coli and P. aeruginosa, 205, In Program and abstracts of the 6th International Symposium on New Quinolones, Denver, Colorado (1998) 22. Oh SH, Ryu EJ, Paek KS, Kim MY, Lee SH and Lee CS, Synthesis and antibacterial activities of LB10827, a new oral cephalosporin antibiotic, Abs. No. F 0397, In Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA (1999) 23. Paek KS, Oh SH, Ryu EJ, Lee CS, and Kim MY, In vitro antibacterial activity of LB10827, a new oral cephalosporin, against respiratory tract pathogens, Abs. No. F 0398, In Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA (1999) 24. Kim MY, Kim SH, Yim HJ, Paek KS, Oh SH, Ryu EJ, and Lee CS, In vivo activity of LB10827, a new oral cephalosporin, in pneumonia infection models, Abs. No. F 0397, In Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco, CA (1999) 25. Kim MY, Duan W, Guzman M, and Hurley LH, Design and biological evaluation of new fluoroquinolones with a dual mechanism of action against topoisomerase II and G- quadruplex, Minisymposium number 2424, In the 93th American Association for Cancer Research, San Francisco, CA (2002) 26. Kim MY and Hurley LH, Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric G-quadruplex, Abs. No. 1246, In Program and abstracts of the 93th American Association for Cancer Research, San Francisco, CA (2002) 27. Vankayalapati H, Kim MY, and Hurley LH, Docking and molecular dynamics simulations of telomestatin: a novel human telomeric G-quadruplex-interactive agent, Abs. No. 3662, In Program and abstracts of the 93th American Association for Cancer Research, San Francisco, CA (2002)

Comments to Webmaster, Last Updated: July 2, 2002
All contents copyright © 2002. Laurence H. Hurley, Ph.D.

1515 North Campbell Avenue
Room 4949
Tucson, Arizona 85724
Phone: 520 626-5621